This product is recommended for the vaccination of healthy horses as an aid in the prevention of disease, viremia, and encephalitis caused by West Nile Virus.
Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject a 1 ml dose by intramuscular route. For primary vaccination, revaccinate with a second 1 ml dose of this product 4 to 6 weeks later. Annual revaccination with a single dose is recommended.
RECOMBITEK® Equine West Nile Virus contains a lyophilized recombinant canarypox vectored West Nile Virus vaccine plus a sterile liquid diluent. A canarypox vector has been modified using recombinant technology to express the desired antigens capable of stimulating a protective immune response to West Nile Virus. After inoculation, the vector does not multiply in the horse, but does express the protective proteins. As a consequence, these components induce an immune status against West Nile Virus. Safety and immunogenicity of this vaccine have been demonstrated by vaccination and challenge tests in susceptible horses.
Immunogenicity of this vaccine has been demonstrated by vaccination and challenge tests in 6 month old healthy horses.
Field Safety testing has demonstrated the Recombitek West Nile Virus Vaccine is safe for use in horses 2 to 4 months of age or older.
Store at 2-7°C (35-45°F). For the preparation and administration of the vaccine, use sterile and antiseptic-free and/or disinfectant-free material. Burn container and all unused contents. Contains gentamicin as a preservative. Do not vaccinate within 21 days prior to slaughter. As with any vaccine, a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
SOLD TO VETERNARIANS ONLY.
Store At 2-7°c (35-45°f).
For Veterinary Use Only.
Manufactured By: MERIAL, INC., Athens, GA 30601 USA
U.S. Vet. Lic. No. 298
RECOMBITEK is a registered trademark, and the HORSE HEAD Logo is a trademark of Merial.
Made in the USA